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We read with interest the study by Qiuhe Wang and colleagues.1 This randomized controlled 
trial aimed to elucidate whether routine stenting plus angioplasty was superior to angioplasty 
alone for preventing restenosis in Budd-Chiari syndrome (BCS) patients with short-length 
stenosis. Authors found that patients treated with angioplasty plus routine stenting had a 
lower incidence of restenosis than patients treated with angioplasty alone without differences 
in survival. Based on these findings, authors suggested that stenting combined with 
angioplasty should be used as a first-line invasive treatment in BCS patients with short-length 
stenosis. 
 
However, we have some concerns about the strength and reproducibility of their findings in 
different cohorts of BCS patients. The extremely long median disease time (13 and 20 years in 
the angioplasty-only and the stenting plus angioplasty groups respectively) before 
randomization, which differs from previous data,2 strongly suggests a huge selection bias 
including mostly surviving patients with, according to table 1 of the manuscript, few symptoms 
(or even asymptomatic). In this regard, a hallmark study from the Clichy group clearly showed 
that there is a group of asymptomatic BCS patients, who usually present large intrahepatic 
venous collaterals that decompress, at least partially, the portal venous system.3 Usually, this 
group of patients has an excellent prognosis and does not require more invasive treatment if 
further thrombosis is prevented by anticoagulation.3 Contrarily, it is difficult to understand 
why patients with severe complications of portal hypertension, such as refractory ascites or 
recurrent variceal bleeding, were excluded. Indeed, these patients may also benefit from 
restoring the physiological hepatic blood outflow, by solving the short-hepatic vein stenosis, 
and avoiding the need of a TIPS.4 It is important to remark that 60% of patients treated with 
angioplasty alone did not develop restenosis and had an excellent survival. Whether similar 
results would have been found if more severe patients would have been included in this study 
is an unanswered question. Unfortunately, the authors did not explore risk factors for 
restenosis in the angioplasty-only group as an attempt to identify the 40% of patients who may 
benefit from early stenting. As already mentioned by the authors and the accompanying 
editorial,1,5 more data about the potential impact of stenting in BCS patients requiring further 
treatments is needed.  
 
Certainly, further studies are needed to answer these questions. Until then, we believe that 
the “wait and see” strategy following angioplasty still has a role in the management of BCS 
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